
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind is well-positioned to see significant revenue growth in the coming years, driven by multiple catalysts such as the potential approval of Afrezza for pediatric use, the approval of the FUROSCIX ReadyFlow autoinjector, and positive results from the MNKD-201 Phase 1b study in IPF patients. The company also has a strong balance sheet and is undervalued compared to its potential revenue and earnings growth potential in the future. These factors make MannKind a promising investment opportunity with a favorable risk-reward scenario.
Bears say
MannKind is currently overvalued with a price target of $10 and has a high risk profile due to its dependence on commercial execution, clinical trials, and regulatory approvals. Despite potential positive developments with their Tyvaso DPI and Ralinepag DPI products, uncertainty surrounding partnership agreements and future sales projections create further risk for investors to consider. With a decline in projected royalty revenue from 2027 onwards and a high amount of risk, it may be best to avoid investing in this stock.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares